- Home
- PLBC vs CLLS Comparison
PLBC vs CLLS Comparison
Compare PLBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- CLLS
- Stock Information
- Founded
- PLBC 1980
- CLLS 1999
- Country
- PLBC United States
- CLLS France
- Employees
- PLBC N/A
- CLLS N/A
- Industry
- PLBC Finance Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- CLLS Health Care
- Exchange
- PLBC Nasdaq
- CLLS Nasdaq
- Market Cap
- PLBC 236.7M
- CLLS 143.4M
- IPO Year
- PLBC 2005
- CLLS 2007
- Fundamental
- Price
- PLBC $45.89
- CLLS $1.59
- Analyst Decision
- PLBC Buy
- CLLS Buy
- Analyst Count
- PLBC 4
- CLLS 1
- Target Price
- PLBC $55.75
- CLLS $4.00
- AVG Volume (30 Days)
- PLBC 14.5K
- CLLS 48.2K
- Earning Date
- PLBC 07-21-2025
- CLLS 08-05-2025
- Dividend Yield
- PLBC 2.62%
- CLLS N/A
- EPS Growth
- PLBC 3.33
- CLLS N/A
- EPS
- PLBC 4.95
- CLLS N/A
- Revenue
- PLBC $84,001,000.00
- CLLS $54,747,000.00
- Revenue This Year
- PLBC $19.95
- CLLS $48.52
- Revenue Next Year
- PLBC $22.19
- CLLS $5.17
- P/E Ratio
- PLBC $9.26
- CLLS N/A
- Revenue Growth
- PLBC 9.14
- CLLS 351.26
- 52 Week Low
- PLBC $35.16
- CLLS $1.10
- 52 Week High
- PLBC $51.33
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- PLBC 55.23
- CLLS 56.98
- Support Level
- PLBC $45.40
- CLLS $1.56
- Resistance Level
- PLBC $46.34
- CLLS $1.49
- Average True Range (ATR)
- PLBC 1.24
- CLLS 0.09
- MACD
- PLBC 0.13
- CLLS 0.01
- Stochastic Oscillator
- PLBC 52.66
- CLLS 80.00
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.